The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,022
Horn, L. A., Riskin, J., Hempel, H., Fousek, K., Lind, H., Hamilton, D. H., McCampbell, K. K., Maeda, D. Y., Zebala, J. A., Su, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000326 · Cited by 90
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 88
Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer
Huang, A., Yang, Y., Shi, J.-Y., Li, Y., Xu, J., Cheng, Y. Q., & Gu, J. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i12.1567 · Cited by 94
ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma
Tang, W., Xu, N., Zhou, J., He, Z., Lenahan, C., Wang, C., Ji, H., Liu, B., Zou, Y., Zeng, H., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01286-w · Cited by 91
Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function
Rancan, C., Arias-Badia, M., Dogra, P., Chen, B., Aran, D., Yang, H., Luong, D., Ilano, A., Li, J., Chang, H., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01448-7 · Cited by 90
Schiavoni, V., Campagna, R., Pozzi, V., Cecati, M., Milanese, G., Sartini, D., Salvolini, E., Galosi, A. B., & Emanuelli, M. (2023) · Cancers · doi:10.3390/cancers15123207 · Cited by 93
Singh, A. K., Winslow, T. B., Kermany, M. H., Goritz, V., Heit, L., Miller, A., Hoffend, N. C., Stein, L. C., Kumaraswamy, L. K., Warren, G. W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2946 · Cited by 89
The potential of organoids in urological cancer research
Wang, S., Gao, D., & Chen, Y. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.65 · Cited by 87
New treatment options for metastatic renal cell carcinoma
Rodríguez‐Vida, A., Hutson, T. E., Joaquim Bellmunt, B., & Strijbos, M. H. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000185 · Cited by 89
The Immunobiology of Kidney Cancer
Drake, C. G., & Stein, M. N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2648 · Cited by 90
Mahadevan, D., Lanasa, M. C., Farber, C. M., Pandey, M. K., Whelden, M., Faas, S. J., Ulery, T. L., Kukreja, A., Li, L., Bedrosian, C. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0710-1 · Cited by 87
Holm, J. S., Funt, S. A., Borch, A., Munk, K. K., Bjerregaard, A.-M., Reading, J. L., Maher, C. A., Regazzi, A. M., Wong, P., Al‐Ahmadie, H. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29342-0 · Cited by 89
Organoid Models for Precision Cancer Immunotherapy
Sun, C., Lan, H., Fang, X., Yang, X., & Jin, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770465 · Cited by 90
Choueiri, T. K., Albiges, L. K., Barthélémy, P., Iacovelli, R., Emambux, S., Molina‐Cerrillo, J., Garmezy, B., Barata, P. C., Basu, A., Bourlon, M. T., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01758-6 · Cited by 87
Self-citationBeckermann, K. E., Jolly, P. C., Kim, J. Y., Bordeaux, J., Puzanov, I. J., Rathmell, W. K., & Johnson, D. B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0206-1 · Cited by 87
Driving cars to the clinic for solid tumors
Castellarin, M. L., Watanabe, K., June, C. H., Kloss, C. C., & Posey, A. D. (2018) · Gene Therapy · doi:10.1038/s41434-018-0007-x · Cited by 87
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
Viale, G., Trapani, D., & Curigliano, G. (2017) · BioMed Research International · doi:10.1155/2017/4719194 · Cited by 89
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2017) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 88
Powles, T. B., Motzer, R. J., Escudier, B. J., Pal, S. K., Kollmannsberger, C., Pikiel, J., Gurney, H., Rha, S. Y., Park, S. H., Geertsen, P. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0164-0 · Cited by 86
Self-citationTargeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 88
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
Labbate, C. V., Hatogai, K., Werntz, R. P., Stadler, W. M., Steinberg, G. D., Eggener, S. E., & Sweis, R. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0546-8 · Cited by 86
Hahn, A. W., Klaassen, Z. W. A., Agarwal, N., Haaland, B. A., Esther, J., Ye, X. Y., Wang, X., Pal, S. K., & Wallis, C. J. D. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.09.002 · Cited by 88
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
Sun, J., Muz, B., Alhallak, K., Markovic, M., Gurley, S., Wang, Z., Guenthner, N., Wasden, K., Fiala, M. A., King, J. A., et al. (2020) · Cancers · doi:10.3390/cancers12020305 · Cited by 87
Alaiwi, S. A., Xie, W., Nassar, A. H., Dudani, S., Martini, D. J., Bakouny, Z., Steinharter, J. A., Nuzzo, P. V., Flippot, R., Chanzá, N. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000144 · Cited by 87
Self-citationAmino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity
Zheng, Y., Yao, Y., Ge, T., Ge, S., Jia, R., Song, X., & Zhuang, A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02845-4 · Cited by 87
Shenoy, N. K., & Pagliaro, L. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw241 · Cited by 88
Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Damayanti, N. P., Budka, J. A., Khella, H. W. Z., Ferris, M. W., Ku, S., KAUFFMAN, E. C., Wood, A. C., Ahmed, K., Chintala, V. N., Adelaiye-Ogala, R. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0269 · Cited by 86
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
Santoni, M., Massari, F., Nunno, V. D., Conti, A., Cimadamore, A., Scarpelli, M., Montironi, R., Liang Cheng, C., Battelli, N., & Antonio Lopez-beltran, B. (2018) · Drugs in Context · doi:10.7573/dic.212528 · Cited by 86
Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1248 · Cited by 85
Petrelli, F., Coinu, A., Vavassori, I., Cabiddu, M., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.04.001 · Cited by 85
The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
McLachlan, J., Boussios, S., Okines, A. F. C., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor, A., Lalondrelle, S., Gore, M. E., Kaye, S. B., et al. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.10.002 · Cited by 85
Giorgi, U. D., Cartenì, G., Giannarelli, D., Basso, U., Galli, L., Cortesi, E., Caserta, C., Pignata, S., Sabbatini, R., Bearz, A., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14461 · Cited by 85
Self-citationTang, T., Abu‐Sbeih, H., Luo, W., Lum, P. J., Qiao, W., Bresalier, R. S., Richards, D. M., & Wang, Y. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1594356 · Cited by 85
Figlin, R. A., Tannir, N. M., Uzzo, R. G., Tykodi, S. S., Chen, D. Y. T., Master, V. A., Kapoor, A., Vaena, D. A., Lowrance, W. T., Bratslavsky, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2427 · Cited by 86
Self-citationRegev, A., Avigan, M., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Bisceglie, A. M. D., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102514 · Cited by 86
Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Liang Cheng, C., Antonio Lopez-beltran, B., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 85
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
Zhong, L., Wu, Q., Chen, F., Liu, J., & Xie, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02803-5 · Cited by 87
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review
Portuguese, A. J., Tykodi, S. S., Blosser, C. D., Gooley, T., Thompson, J. A., & Hall, E. T. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7009 · Cited by 85
Self-citationTreatment strategies for clear cell renal cell carcinoma: Past, present and future
Yang, J., Wang, K., & Yang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1133832 · Cited by 91
Sridharan, V., Margalit, D. N., Lynch, S. A., Severgnini, M., Zhou, J. M., Chau, N. G., Rabinowits, G., Lorch, J. H., Hammerman, P. S., Hodi, F. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.166 · Cited by 91
Hypermutation and microsatellite instability in gastrointestinal cancers
Yuza, K., Nagahashi, M., Watanabe, S., Takabe, K., & Wakai, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22783 · Cited by 90
Radiation therapy and the abscopal effect: a concept comes of age
Ng, J., & Dai, T. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.01.32 · Cited by 87
George, S., Rini, B. I., & Hammers, H. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4604 · Cited by 84
Self-citationWells, J. C., Stukalin, I., Norton, C. K., Srinivas, S., Lee, J., Donskov, F. N., Bjarnason, G. A., Yamamoto, H., Beuselinck, B., Rini, B. I., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.049 · Cited by 84
Self-citationTanaka, R., Maruyama, H., Tomidokoro, Y., Yanagiha, K., Hirabayashi, T., Ishii, A., Okune, M., Inoue, S., Sekine, I., Tamaoka, A., et al. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw090 · Cited by 84
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
Maxwell, R., Jackson, C. M., & Lim, M. K. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0492-y · Cited by 86
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 85
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Haratani, K., Yonesaka, K., Takamura, S., Maenishi, O., Kato, R., Takegawa, N., Kawakami, H., Tanaka, K., Hayashi, H., Takeda, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126598 · Cited by 85
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 85
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85
Incorvaia, L., Fanale, D., Badalamenti, G., Porta, C., Olive, D., Luca, I. D., Brando, C., Rizzo, M., Messina, C. G. M., Rediti, M., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1832348 · Cited by 88
Patient-derived xenografts as in vivo models for research in urological malignancies
Inoue, T., Terada, N., Kobayashi, T., & Ogawa, O. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.19 · Cited by 88
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Immune Checkpoint Inhibitors Side Effects and Management
Kourié, H. R., & Klastersky, J. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0029 · Cited by 83
Huang, K. C., Chiang, S., Ke, T., Chen, T.-W., You, Y., Chen, W. T., & Chao, K. S. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-33927-5 · Cited by 86
Correlation between patients' age and cancer immunotherapy efficacy.
Wu, Q., Wang, Q., Tang, X., Xu, R., Zhang, L., Chen, X., Xue, Q., Wang, Z., Shi, R., Wang, F., et al. (2019) · Europe PMC (PubMed Central) · doi:10.1080/2162402x.2019.1568810 · Cited by 84
Menyhárt, O., & Győrffy, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09854-1 · Cited by 91
Impact of age on the toxicity of immune checkpoint inhibition
Samani, A., Zhang, S., Spiers, L., Suwaidan, A. A., Merrick, S., Tippu, Z., Payne, M., Faust, G. E. S., Papa, S., Fields, P. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000871 · Cited by 86
Ficial, M., Jegede, O. A., Sant’Angelo, M., Hou, Y., Flaifel, A., Pignon, J., Braun, D. A., Wind‐Rotolo, M., Sticco-Ivins, M. A., Catalano, P. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3084 · Cited by 86
Self-citationTsuruta, A., Shiiba, Y., Matsunaga, N., Fujimoto, M., Yoshida, Y., Koyanagi, S., & Ohdo, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0786 · Cited by 87
Ipilimumab and Bevacizumab in Glioblastoma
Carter, T. J., Shaw, H. M., Cohn-Brown, D., Chester, K. A., & Mulholland, P. J. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.04.042 · Cited by 84
Bamias, A., Escudier, B. J., Sternberg, C. N., Zagouri, F., Dellis, A., Djavan, B., Tzannis, K., Kontovinis, L., STRAVODIMOS, K. G., Papatsoris, A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0435 · Cited by 82
Self-citationHuang, Q., Zhang, H., Hai, J., Socinski, M. A., Lim, E. K. S., Chen, H., & Stebbing, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1396403 · Cited by 82
Meyer, E., Pasquier, D., Bernadou, G., Calais, G., Maroun, P., Bossi, A., Théodore, C., Albiges, L. K., Stefan, D., de Crevoisier, R., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.04.008 · Cited by 82
An, Y., Wu, Z., Wang, N., Yang, Z., Li, Y., Xu, B., & Sun, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02404-x · Cited by 82
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 84
Carretero-González, A., Lora, D., Martín-Sobrino, I., Sanz, I. S., Bourlon, M. T., Herranz, U. A., Chanzá, N. M., Castellano, D., & de Velasco, G. (2020) · Cancers · doi:10.3390/cancers12071945 · Cited by 84
Self-citationMatsukane, R., Watanabe, H., Minami, H., Hata, K., Suetsugu, K., Tsuji, T., Masuda, S., Okamoto, I., Nakagawa, T., Ito, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79397-6 · Cited by 83
Terry, S., Dalban, C., Rioux-Leclercq, N. C., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0972 · Cited by 85
Self-citationT-cell repertoire diversity: friend or foe for protective antitumor response?
Porciello, N., Franzese, O., D’Ambrosio, L., Palermo, B., & Nisticò, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02566-0 · Cited by 88
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
Ding, L., Chen, X., Zhang, W., Dai, X., Guo, H., Pan, X., Xu, Y., Feng, J., Yuan, M., Gao, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci154754 · Cited by 84
Newly developed 3D in vitro models to study tumor–immune interaction
Mu, P., Zhou, S., Lv, T., Xia, F., Shen, L., Wan, J., Wang, Y., Zhang, H., Cai, S., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02653-w · Cited by 87
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
Siefker-Radtke, A. O., & Curti, B. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.190 · Cited by 82
Phase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81
Horisberger, A., La Rosa, S., Zurcher, J.-P., Zimmermann, S., Spertini, F., Coukos, G., & Obeid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0481-0 · Cited by 81
Beyond Melanoma: Inhibiting The PD-1/PD-L1 Pathway in Solid Tumors
Gentzler, R. D., Hall, R. D., Kunk, P. R., Gaughan, E. M., Dillon, P. M., Slingluff, C. L., & Rahma, O. E. (2016) · Immunotherapy · doi:10.2217/imt-2015-0029 · Cited by 81
Powles, T. B., Sarwar, N., Stockdale, A. D., Sarker, S., Boleti, E., Protheroe, A. S., Jones, R. J., Chowdhury, S., Peters, J., Oades, G. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1197 · Cited by 81
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Naidoo, J., Cappelli, L. C., Forde, P. M., Marrone, K. A., Lipson, E. J., Hammers, H. J., Sharfman, W. H., Le, D. T., Baer, A. N., Shah, A. A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0390 · Cited by 81
Self-citationStromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients
Wyss, J., Dislich, B., Koelzer, V. H., Galván, J. A., Dawson, H., Hädrich, M., Inderbitzin, D., Lugli, A., Zlobec, I., & Berger, M. D. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.09.007 · Cited by 82
Mitchell, E. L., Lau, P. K. H., Khoo, C. C. H., Liew, D. F. L., Leung, J., Liu, B., Rischin, A., Frauman, A. G., Kee, D., Smith, K. M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.027 · Cited by 81
Guo, G., Wang, Y., Zhou, Y., Quan, Q., Zhang, Y., Wang, H., Zhang, B., & Xia, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0656-3 · Cited by 81
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 83
A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma
Alchahin, A. M., Mei, S., Τσέα, Ι., Hirz, T., Kfoury, Y. S., Dahl, D. M., Wu, C., Subtelny, A. O., Wu, S., Scadden, D. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33375-w · Cited by 86
Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., Yin, X., Ge, M., Xiang, X., Ying, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02605-9 · Cited by 86
Li, J., Wang, K., Yang, C., Zhu, K., Jiang, C., Wang, M., Zhou, Z., Tang, N., Wang, Q., Wang, S., et al. (2023) · Advanced Science · doi:10.1002/advs.202207067 · Cited by 82
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Ong, M., Ibrahim, A. M., Bourassa‐Blanchette, S., Canil, C., Fairhead, T., & Knoll, G. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0171-8 · Cited by 81
Cancer Immunology and Immunotherapy
Sukari, A. W., Nagasaka, M., Al‐Hadidi, A., & Lum, L. G. (2016) · Anticancer Research · doi:10.21873/anticanres.11144 · Cited by 81
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Hailemichael, Y., Woods, A. N., Fu, T., He, Q., Nielsen, M. C., Hasan, F., Roszik, J., Xiao, Z., Vianden, C., Khong, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93303 · Cited by 81
Self-citationSevere Esophagitis and Gastritis from Nivolumab Therapy
Boike, J. R., & DeJulio, T. J. (2017) · ACG Case Reports Journal · doi:10.14309/crj.2017.57 · Cited by 80
Takahashi, N., Iwasa, S., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., & Yamada, Y. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2184-6 · Cited by 81
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Soliman, H. H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s122974 · Cited by 81
Mulkey, F. A., Theoret, M. R., Keegan, P., Pazdur, R., & Sridhara, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000146 · Cited by 80
Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.001 · Cited by 79
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Svetlovska, D., Kalavska, K., Rejlekova, K., Spanik, S., Kajo, K., Babal, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15585 · Cited by 79
Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion
Kushnir, I., & Wolf, I. (2016) · Cardiology · doi:10.1159/000447053 · Cited by 79
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Long, J., Zhang, Q., & Rongxin, Z. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0086 · Cited by 82
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Flippot, R., Escudier, B. J., & Albiges, L. K. (2018) · Drugs · doi:10.1007/s40265-018-0970-y · Cited by 79
Self-citationRivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 79
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
